SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/59637"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/59637" > Randomized trial co...

  • Rudenstam, Carl-Magnus,1930Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences (författare)

Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.

  • Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

  • 2006

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/59637
  • https://gup.ub.gu.se/publication/59637URI
  • https://doi.org/10.1200/JCO.2005.01.5784DOI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information but is associated with undesirable morbidity. We therefore investigated whether avoiding axillary surgery in older women would result in improved quality of life (QL) with similar disease-free survival (DFS) and overall survival (OS). PATIENTS AND METHODS: Between 1993 and 2002, women > or = 60 years old with clinically node-negative operable breast cancer in whom adjuvant tamoxifen was considered indicated regardless of pathologic nodal status were randomly assigned to primary surgery plus axillary clearance (Sx + Ax) followed by tamoxifen (Tam) versus Sx without Ax followed by Tam for 5 consecutive years. The primary end point was QL reported by the patient and by physician assessment. RESULTS: A total of 473 patients (234 to Sx + Ax, 239 to Sx) were randomly assigned. The median age was 74 years; 80% had estrogen receptor-positive disease. In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment, but the differences tended to disappear in 6 to 12 months. At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77). CONCLUSION: Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.

Ämnesord och genrebeteckningar

  • Aged
  • Aged
  • 80 and over
  • Antineoplastic Agents
  • Hormonal
  • therapeutic use
  • Axilla
  • Breast Neoplasms
  • chemistry
  • mortality
  • pathology
  • prevention & control
  • surgery
  • Chemotherapy
  • Adjuvant
  • Disease-Free Survival
  • Estrogen Receptor Modulators
  • therapeutic use
  • Female
  • Humans
  • Lymph Node Excision
  • adverse effects
  • Lymphatic Metastasis
  • Mastectomy
  • methods
  • Middle Aged
  • Quality of Life
  • Radiotherapy
  • Adjuvant
  • Receptors
  • Estrogen
  • analysis
  • Survival Analysis
  • Tamoxifen
  • therapeutic use
  • Treatment Outcome

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Zahrieh, David (författare)
  • Forbes, John F (författare)
  • Crivellari, Diana (författare)
  • Holmberg, Stig B,1946Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences (författare)
  • Rey, Piercarlo (författare)
  • Dent, David (författare)
  • Campbell, Ian (författare)
  • Bernhard, Jürg (författare)
  • Price, Karen N (författare)
  • Castiglione-Gertsch, Monica (författare)
  • Goldhirsch, Aron (författare)
  • Gelber, Richard D (författare)
  • Coates, Alan S (författare)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of clinical oncology : official journal of the American Society of Clinical Oncology24:3, s. 337-441527-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy